Skip to main content

Table 1 Patients’ characteristics

From: The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients

Patient Characteristics

Total

Without event

With event

P

Age (years)

3.636±2.166

3.264±2.131

4.008±2.194

0.402

Gender

 Male

14(36.8%)

5(26.3%)

9(47.4%)

0.313

 Female

24(63.2%)

14(73.7%)

10(52.6%)

 

Tumor primary site

 Abdomen

34(89.5%)

16(84.2%)

18(94.7%)

0.604

 Non-Abdomen

4(10.5%)

3(15.8%)

1(5.3%)

 

INSS

 Stage 1

2(5.3%)

2(10.5%)

0(0.0%)

0.178

 Stage2

1(2.6%)

1(5.3%)

0(0.0%)

 

 Stage3

6(15.8%)

4(21.1%)

2(10.5%)

 

 Stage4

29(76.3%)

12(63.1%)

17(89.5%)

 

COG

 Low risk

2(5.3%)

2(10.5%)

0(0.0%)

0.027*

 medium risk

14(36.8%)

10(52.6%)

4(21.1%)

 

 high risk

22(57.9%)

7(36.9%)

15(78.9%)

 
  1. INSS International Neuroblastoma Staging System, COG Children's Oncology Group, *P < 0.05